Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells Haijun ZhangGang LiuGuojun Wu Preclinical Study 12 December 2007 Pages: 217 - 227
Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers Logan C. WalkerNic WaddellAmanda B. Spurdle Preclinical Study 20 December 2007 Pages: 229 - 236
Targeted disruption of Brca1 in restricted compartments of the mouse mammary epithelia Chanel E. SmartCatherine ClarkeMelissa A. Brown Preclinical Study 20 December 2007 Pages: 237 - 241
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms Erika B. SchulzeBenjamin D. HedleyAlison L. Allan Preclinical Study 21 December 2007 Pages: 243 - 254
Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of α-difluoromethylornithine (DFMO) in breast cancer cells Haifang XuSharlene WashingtonAndrea Manni Preclinical Study 21 December 2007 Pages: 255 - 261
Dickkopf-1 mediated tumor suppression in human breast carcinoma cells Andrei M. MikheevSvetlana A. MikheevaHelmut Zarbl Preclinical Study 22 December 2007 Pages: 263 - 273
YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer Anne RoslindAnn S. KnoopEva Balslev Preclinical Study 22 December 2007 Pages: 275 - 285
Id-1 regulates Bcl-2 and Bax expression through p53 and NF-κB in MCF-7 breast cancer cells Hwan KimHeekyoung ChungGu Kong Preclinical Study 25 December 2007 Pages: 287 - 296
Towards an optimized platform for the detection, enrichment, and semi-quantitation circulating tumor cells T. J. MolloyA. J. BosmaLaura J. van’t Veer Preclinical Study 23 January 2008 Pages: 297 - 307
The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07) Susanne TaucherGuenther G. StegerMichael Gnant Clinical Trial 14 December 2007 Pages: 309 - 316
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib John P. CrownHarold A. Burris IIISteve Chan Clinical Trial 20 January 2008 Pages: 317 - 325
Reproducibility of ductal lavage cytology and cellularity over a six month interval in high risk women Deepa B. PatilHeather A. LankesSeema A. Khan Clinical Trial 21 December 2007 Pages: 327 - 333
Circulating transforming growth factor-β-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study Ana M. GrauWanqing WenWei Zheng Epidemiology 13 December 2007 Pages: 335 - 341
Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations Ian J. SeymourSilvia CasadeiDaniele Calistri Epidemiology 20 December 2007 Pages: 343 - 349
Breast cancer risk and the BRCA1 interacting protein CTIP Kylie L. GorringeDavid Y. H. ChoongIan G. Campbell Epidemiology 20 December 2007 Pages: 351 - 352
Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1 M. D. MiramarM. T. CalvoA. García de Jalón Epidemiology 04 January 2008 Pages: 353 - 358
Familial association of laryngeal, lung, stomach and early-onset breast cancer Ewa JaworowskaPablo Serrano-FernándezJan Lubiński Epidemiology 21 December 2007 Pages: 359 - 361
The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer H. ClarW. RennerU. Langsenlehner Letter to the Editor 15 December 2007 Pages: 363 - 365
A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population Cezary CybulskiDominika WokołorczykSteven A. Narod Letter to the Editor 21 December 2007 Pages: 367 - 368
Letrozole in the extended adjuvant setting: MA.17 Paul E. Goss Erratum 15 January 2008 Pages: 369 - 369
Letrozole in the neoadjuvant setting the P024 trial Matthew J. EllisCynthia Ma Erratum 13 December 2007 Pages: 371 - 371
Safety of aromatase inhibitors in the adjuvant setting Edith A. Perez Erratum 13 December 2007 Pages: 379 - 379
Femara® and the future: tailoring treatment and combination therapies with Femara Matthew EllisCynthia Ma Erratum 13 December 2007 Pages: 383 - 383
The discovery and mechanism of action of letrozole Ajay S. Bhatnagar Erratum 13 December 2007 Pages: 385 - 385
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98 Dieter KoeberleBeat Thuerlimann Erratum 13 December 2007 Pages: 387 - 387